Oramed Pharmaceuticals Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Oramed Pharmaceuticals Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $-55 of operating cash. Lower than 97% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$-55Over the last 3 years, every $100 of reported profit came with $-55 of operating cash.
Lower than 97% of Healthcare companies in United States.
Self-Funding Ratio
-12.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 53% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 26%
Sales fell 26% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-26% / +43%In 3 years sales changed by -26% while total assets changed by +43%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-32.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 65% of Healthcare companies in United States.
Cash Cushion Ratio
+73%Cash, after subtracting all debt, equals 73% of its market value (net cash).
Higher than 83% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Oramed Pharmaceuticals Inc. owes $0.14 for every $1 it owns. Oramed Pharmaceuticals Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
1.0Investors pay $1.0 for every $1 of Oramed Pharmaceuticals Inc.'s yearly profit, lower than 93% of Healthcare companies in United States.
P/B ratio
0.54The share price is 0.54 times Oramed Pharmaceuticals Inc.'s book value per share, lower than 90% of Healthcare companies in United States.
Market cap
$171 MThe total market value of all of Oramed Pharmaceuticals Inc.'s shares at today's price (share price × number of shares), smaller than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$317 MWhat Oramed Pharmaceuticals Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$7.63Net worth divided by the number of shares. The share price of $4.12 is 0.5 times this, which is the P/B above.
Return on equity (ROE)
74.2%Oramed Pharmaceuticals Inc. earned 74.2% on its shareholders' money over the last year, higher than 98% of Healthcare companies in United States.
Owes vs Owns
0.14×Oramed Pharmaceuticals Inc. owes $0.14 for every $1 it owns (low), lower than 81% of Healthcare companies in United States.
Dividend yield
6.04%Oramed Pharmaceuticals Inc. pays 6.04% of its share price as dividends a year, higher than 97% of dividend-paying Healthcare companies in United States.
Profit growth
Back to profitOramed Pharmaceuticals Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
3202.5%Oramed Pharmaceuticals Inc. keeps $3202 of every $100 of revenue as net profit.
Cash quality
-0.1×Cash from Oramed Pharmaceuticals Inc.'s business was -0.1× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Cash vs debt
Net cashOramed Pharmaceuticals Inc. held $125 M more cash than debt (net cash) at Dec 2025.
Questions
What is Oramed Pharmaceuticals Inc.'s P/E ratio?
Investors pay $1.0 for every $1 of Oramed Pharmaceuticals Inc.'s yearly profit, lower than 93% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Oramed Pharmaceuticals Inc.: $171 M ÷ $317 M (30 Jun 2026) = 0.5.
What is Oramed Pharmaceuticals Inc.'s return on equity?
Oramed Pharmaceuticals Inc. earned 74.2% on its shareholders' money over the last year, higher than 98% of Healthcare companies in United States.
How much does Oramed Pharmaceuticals Inc. owe compared with what it owns?
Oramed Pharmaceuticals Inc. owes $0.14 for every $1 it owns (low), lower than 81% of Healthcare companies in United States.
Does Oramed Pharmaceuticals Inc. pay a dividend?
Yes. Oramed Pharmaceuticals Inc. pays 6.04% of its share price as dividends a year, higher than 97% of dividend-paying Healthcare companies in United States.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.